Click on the picture below to see the presentation :

The dramatic rise in global finfish aquaculture has been accompanied by a decrease in medicine availability. The global aquatic health market is estimated at approximately 800 million dollars with Europe representing about 24% of sales. The reasons for limited medicines availability are principally the cost of the licensing process, variation in data requirements between  countries and high cost of the licensed products.  Fish imported into Europe have often been tested with generic or unlicensed products, creating unfair competition in the market place. The problems of the licensing process will be illustrated with examples e.g. field trial cost, difficulty in obtaining sufficient numbers of fish for ATC testing and issues such as modelling methodology. Research requirements will also be discussed and include topics such as detection methods, vaccine development and batch testing problems,  inheritable resistance, epidemiology and immunology and environmental effects.

Professor Randolph Richards is the Director of the Institute of Aquaculture at the University of Stirling (UK),Director of Aquaculture Project Development Ltd and Director of Alkioni Ltd (a bass and bream farming company based in Cyprus). Professor Randolphs is also Veterinary Adviser to Scottish Salmon Growers Association (now Scottish Quality Salmon), Member of Scientific Panel of Salmon and Trout Association, Member of Royal College of Veterinary Surgeons, Regular adviser to international bodies (such as FAO, World Bank, Council of Europe,Lloyds of London), Founder member of the Veterinary Association for Arbitration and Jurisprudence ...

Contact details :Institute of Aquaculture, University of Stirling, Stirling FK9 4LA,  Scotland, UK, rhr2@stir.ac.uk .